Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06646783 | Phase IIT Trial of SNA014 | not yet recruiting | Early Phase 1 | 28 | SmartNuclide BiopharmaINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06639971 | Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC(RIO-HCC) | not yet recruiting | — | 500 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06641453 | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643533 | Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004) | not yet recruiting | — | 15 | Fujian Provincial HospitalOTHER | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06645314 | Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 16 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06464380 | Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 40 | Ain Shams UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06592612 | Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment | not yet recruiting | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06602986 | Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma | not yet recruiting | N/A | 96 | Pak Emirates Military HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06538935 | SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Fujian Cancer HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06535737 | A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab(CPAB) | not yet recruiting | Phase 2 | 40 | Chulalongkorn UniversityOTHER | 0 | Aug 2, 2024 | clinicaltrials |
| NCT06276803 | The LINFU® U.S. Registry for the in the General Population Without Risk Factors | not yet recruiting | — | 500 | Adenocyte, LLCINDUSTRY | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06512467 | Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06496815 | Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy | not yet recruiting | Phase 4 | 32 | Tongji HospitalOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT06492317 | RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer | not yet recruiting | Phase 2 | 20 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06454435 | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer | not yet recruiting | Phase 2 | 158 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06449846 | Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma | not yet recruiting | — | 152 | Zhujiang HospitalOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06439550 | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | not yet recruiting | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jun 3, 2024 | clinicaltrials |
| NCT06067620 | Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy(PRORHEM) | not yet recruiting | N/A | 70 | Jeremy MeyerOTHER | 0 | May 10, 2024 | clinicaltrials |
| NCT06399172 | OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy(OSPRItaly) | not yet recruiting | — | 50 | OncoSil Medical LimitedINDUSTRY | 0 | May 3, 2024 | clinicaltrials |
| NCT06089369 | Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | not yet recruiting | Phase 3 | 360 | Tongji HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06375317 | HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure | not yet recruiting | Phase 2 | 42 | Yehua ShenOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT06364787 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06361030 | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06331260 | Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 600 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06331273 | Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 800 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06317896 | Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS | not yet recruiting | — | 82 | Zhujiang HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06311916 | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. | not yet recruiting | Phase 4 | 312 | Chen XiaopingOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06253598 | Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT06272162 | Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy(LAPSTAR) | not yet recruiting | N/A | 150 | UMC UtrechtOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06196775 | A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 36 | Harbin Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06195670 | Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC | not yet recruiting | Phase 1 / Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06178939 | Effects of Cognitive Intervention Therapy on Postoperative Delirium | not yet recruiting | N/A | 60 | Yonsei UniversityOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06060847 | Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS)(LIRESS) | not yet recruiting | N/A | 50 | Ospedale V. FazziOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06168357 | Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma . | not yet recruiting | — | 55 | Assiut UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06089382 | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection | not yet recruiting | Phase 3 | 104 | Tongji HospitalOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05978882 | Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4) | not yet recruiting | N/A | 203 | National Cancer Center, KoreaOTHER_GOV | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05976568 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 668 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05971628 | Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma(RAPID-HCC) | not yet recruiting | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05970627 | Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | not yet recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05954117 | Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia(CHIFMEOE) | not yet recruiting | N/A | 60 | University Hospital, Clermont-FerrandOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05897138 | A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05895214 | Mesopancreas Study in Pancreatic Cancer(MESOPANC-01) | not yet recruiting | — | 500 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05887505 | Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy | not yet recruiting | N/A | 120 | Taoyuan General HospitalOTHER_GOV | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05752890 | A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma | not yet recruiting | — | 95 | National Taiwan University HospitalOTHER | 0 | Mar 3, 2023 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05602974 | Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study | not yet recruiting | N/A | 140 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT05718232 | SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)(SEARCH) | not yet recruiting | Phase 3 | 136 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05611359 | Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer(HOPE-1) | not yet recruiting | N/A | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Nov 10, 2022 | clinicaltrials |
| NCT03857737 | Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer | not yet recruiting | N/A | 300 | Peking University Third HospitalOTHER | 1 | Feb 28, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 17, 2024source: clinicaltrials